Cerebellar Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Alcohol Use Disorder

Not Applicable

Completed

• Conditions: Alcohol Use Disorder
• Interventions: Device: Sham transcranial magnetic stimulation; Device: Repetitive transcranial magnetic stimulation (rTMS)

• Registration Number: NCT03829761
• Lead Sponsor: The Mind Research Network

Brief Summary

The objective of the current study is to investigate the effects of repetitive transcranial magnetic stimulation (rTMS) on self-reported negative affect, cerebellar brain activation and alcohol use outcomes in alcohol use disorder (AUD).

Detailed Description

To achieve study aims, 34 treatment seeking adults with AUD will be recruited from local intensive outpatient (IOP) treatment programs and randomized to treatment with either inhibitory 1Hz rTMS to cerebellar vermis given daily for 2 weeks (total of 10 sessions) or sham. Alcohol use outcomes, self-reported negative affect, and craving will be obtained at baseline, 1 day, 1 week and 6 weeks following rTMS termination. An fMRI scan during a Stroop task will be obtained at baseline and 1 day after the final rTMS session.

Study Timeline

• Study First Submitted: 2018-11-07
• Study First Submitted QC: 2019-02-01
• Study First Posted: 2019-02-04
• Study Start: 2019-02-20
• Primary Completion: 2023-09-07
• Study Completion: 2023-09-07
• Status Verified: 2023-10
• Last Update Submitted: 2023-10-19
• Last Update Posted: 2023-10-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

• Males and females age 18-65 meeting DSM-V criteria for moderate or severe AUD in the past year;
• Interested in cutting down or quitting drinking;
• Able to provide voluntary informed consent;
• Have at least 4 heavy drinking days (≥ 5 drinks per day for men, and ≥4 for women) in the past 60 days;
• Currently receiving treatment for alcohol use disorder.

Read More

Exclusion Criteria

• Severe neurological conditions (TBI/stroke/history of a seizure/dementia and other significant cognitive illnesses);
• Other urgent medical problems, as determined by the study physician from the history and physical exam;
• Schizophrenia, schizoaffective disorder, bipolar I disorder
• Suicidal thoughts (intent or plan) in the last month;
• Current moderate or severe other SUD (except nicotine or marijuana) or other drug (except nicotine or marijuana) use in the past month;
• Active legal problems with the potential to result in incarceration;
• Pregnancy or lactation, or child bearing age and sexually active but not on birth control (barrier methods allowed);
• Current daily use of anti-craving medications, antidepressants (at doses considered therapeutic for depression), benzodiazepines, antipsychotics (at doses considered therapeutic for psychosis or mood stabilization), mood stabilizers (at doses considered therapeutic for mood stabilization);
• Have previously undergone rTMS (to assure the blind is effective);
• Personal or familial (in first degree relatives) history of epilepsy;
• Any contraindication for Magnetic Resonance Imaging (MRI) or TMS including metal shards or certain implants (pacemakers etc.) in the body.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Sham TMS	Sham transcranial magnetic stimulation	Sham TMS. Sham transcranial magnetic stimulation to cerebellar vermis.
Cerebellar rTMS	Repetitive transcranial magnetic stimulation (rTMS)	Cerebellar rTMS. 1Hz repetitive transcranial magnetic stimulation (rTMS) to cerebellar vermis.

Primary Outcome Measures

Name	Time	Method
Change in percent days abstinent as measured by the Time Line Follow Back	3 weeks	Change in percent days abstinent as measured by the Time Line Follow Back from the 90 days prior to day 1 to day 14-21 (post-treatment).
Change in self reported negative affect as measured by the Promise anger, anxiety and depression scales	2 weeks	Change in self reported negative affect as measured by the Promise anger, anxiety and depression scale T scores from baseline to day 15 (post-treatment).
Time to drinking relapse as measured by the Time Line Follow Back	8 weeks	Time to drinking relapse as measured by the Time Line Follow Back from baseline in days.
Change in cerebellar brain activation as indicated by percent signal change in the medial cerebellum during incongruent minus congruent trials during a multisensory Stroop task during fMRI	2 weeks	Change in cerebellar brain activation as indicated by percent signal change in the medial cerebellum during incongruent minus congruent trials during a multisensory Stroop task during fMRI from baseline to day 15 (post-treatment). This will be calculated using a mask derived from preliminary data from a sample of 33 individuals with AUD at a single timepoint. Activation in this brain region was correlated with depression, anxiety, and recent drinking. Manuscript describing this result is under review (Wilcox et al.), and another manuscript describes the task in question (Wilcox et al. 2014 Cognitive Control Network Function in Alcohol Use Disorder Before and During Treatment With Lorazepam. Subst Use Misuse.

Trial Locations

Locations (1)

The Mind Research Network; 🇺🇸 Albuquerque, New Mexico, United States